Download Free Sample Report

Global Recombinant Erythropoietin Drugs Market Research Report 2022

Global Recombinant Erythropoietin Drugs Market Research Report 2022

  • Published on : 27 October 2022
  • Pages :96
  • Report Code:SMR-7464864

Download Report PDF Instantly

Leave This Empty:

Secure

Report overview

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

  • rhEPO
  • Erythropoiesis-Stimulating Agents (ESA)

Segment by Application

  • Chronic Kidney Disease
  • Cancer Related Anemia
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Taiwan
  • Indonesia
  • Thailand
  • Malaysia
  • Philippines
  • Vietnam
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • U.A.E

By Company

  • Amgen
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Roche
  • 3SBio Group
  • Celltrion, Inc
  • Teva Pharmaceutical Industries Ltd
  • F. Hoffmann-La Roche Ltd
  • LG Life Sciences Ltd
  • Biocon Limited
  • Intas Pharmaceuticals Ltd
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy's Laboratories Ltd